# Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

> **NCT05938361** · — · ACTIVE_NOT_RECRUITING · sponsor: **Clin4all** · enrollment: 120 (estimated)

## Conditions studied

- Psoriasis Palmaris
- Psoriasis Genital
- Psoriasis of Scalp
- Psoriasis Plantaris
- Psoriasis Nail

## Interventions

- **OTHER:** Psoriasis clinical assessments
- **OTHER:** Quality of life evaluation
- **OTHER:** Satisfaction assessment
- **OTHER:** Pruritus evaluation

## Key facts

- **NCT ID:** NCT05938361
- **Lead sponsor:** Clin4all
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-10-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938361, "Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05938361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*